Zoetis(US:ZTS) ZACKS·2025-12-23 00:16Company Performance - Zoetis (ZTS) closed at $123.78, reflecting a +1.26% change from the previous day's closing price, outperforming the S&P 500's gain of 0.64% [1] - The stock has increased by 0.15% over the past month, underperforming the Medical sector's gain of 2.25% and the S&P 500's gain of 3% [1] Upcoming Earnings - Analysts forecast Zoetis to report an EPS of $1.4, indicating no change from the same quarter last year, with expected quarterly revenue of $2.36 billion, up 1.89% year-over-year [2] Full-Year Estimates - The Zacks Consensus Estimates for Zoetis project earnings of $6.34 per share and revenue of $9.44 billion, representing year-over-year increases of +7.09% and +2%, respectively [3] Analyst Estimates and Stock Performance - Recent changes in analyst estimates for Zoetis are crucial as they often indicate shifts in near-term business trends, with positive revisions suggesting a favorable business outlook [3] - The Zacks Rank system, which incorporates estimate changes, has shown that stocks ranked 1 (Strong Buy) have yielded an average annual return of +25% since 1988 [4][5] Valuation Metrics - Zoetis is currently trading at a Forward P/E ratio of 19.3, which is lower than the industry average of 19.43 [6] - The company has a PEG ratio of 2.66, compared to the Medical - Drugs industry average PEG ratio of 1.17 [6] Industry Ranking - The Medical - Drugs industry, which includes Zoetis, holds a Zacks Industry Rank of 70, placing it in the top 29% of over 250 industries [7]